Form 8-K Revance Therapeutics, For: Nov 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Revance Therapeutics (RVNC) Misses Q3 EPS by 92c; Offers Guidance
November 8, 2023 4:50 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.63), $0.92 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $56.8 million versus the consensus estimate of $59.29 million.
In September 2023, Revance revised its 2023 GAAP and Non-GAAP operating expense guidance to reflect... More
